As Program Manager for the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), my work focuses on the value of new technologies and how to most effectively and efficiently implement them into health care, with a particular focus on personalized (or precision) medicine...
My research considers the role of scientific evidence and interest group lobbying in decision making on public health. This work uses multiple data sources including internal industry documents, campaign finance reports, administrative datasets, and interviews.
Health policy expert Lisa Bero, PhD, is hailed in the latest issue of The Lancet for tackling hot-button subjects such as financial biases in drug research.
Every year U.S. drug regulators approve dozens of new medicines as “safe and effective,” but just how effective are they? How well do they alleviate specific aspects of illness, whether light sensitivity from migraine headaches or itching from eczema?
Partners in D student pharmacists counsel seniors.
Partners in D, the innovative program in which UCSF student pharmacists help both underserved seniors and fellow health professionals maximize the complex Medicare Part D drug benefit, has won a national award for community service.
Left to right: Rifkind Award winners Angela Anson, Megan McCurdy, and Donna Odierna
The 13th annual Spring Research Seminar highlighting work by students, residents, and faculty members in the UCSF School of Pharmacy Department of Clinical Pharmacy—and featuring 48 project posters—was held May 3, 2011 on UCSF’s Parnassus campus.
A student-pharmacist-led, California statewide teaching program for physicians, medical students, and other health care providers is successfully demonstrating the importance of health policy literacy and interprofessional education at a time in the U.S. that begs for systemic reforms.
The wider world use of medical tests and treatments based on individual genetic differences is the focus of a new, US$5 million research program funded by the National Cancer Institute (NCI) and led by UCSF School of Pharmacy health economist Kathryn Phillips,
